Psychedelic Stocks Archives - Page 53 of 61

MondayApr 25, 2022 1:00 pm

Three Kinds of Trauma Psychedelics Hope to Treat

Currently, there are a number of ongoing and planned clinical trials looking into the use of psychedelic therapies in the treatment of post-traumatic stress disorder (PTSD). Most of these trials focus on one particular psychedelic, MDMA, which is commonly known as ecstasy. However, other psychedelic compounds have also shown therapeutic potential, especially with regard to treating trauma. Given that trauma comes in different forms, researchers are focused on addressing the primary/root causes of trauma using psychedelics. Here we discuss broad categorizations of trauma being targeted by psychedelics. Trauma and sexual and emotional abuse Research has found that psychedelics may be…

FridayApr 22, 2022 11:47 am

GoDaddy Billionaire Owner Supports Use of Psychedelics as Treatment for PTSD

Over the past couple of years, there has been increased interest in psychedelics as alternative treatments for mental disorders. With most mental health medications causing side effects such as muscle spasms, nausea, constipation and loss of sex drive, there has been a push for safer alternative medications. Studies show that psychedelics have the potential to treat mental disorders, including post-traumatic stress disorder (PTSD), major depressive disorder, anorexia nervosa and alcohol-use disorder. Mental health conditions take nearly 8 million lives every year and cost the world billions of dollars in lost productivity. According to the National Institute of Mental Health (NIMH),…

ThursdayApr 21, 2022 3:07 pm

Why MindMed’s LSD Trial for Anxiety May Be Important to Psychedelic Investors

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) is set to present preliminary topline effectiveness and safety results from its phase IIa study, which involves the treatment of anxiety disorder using LSD in conjunction with therapy. Many, including investors, expect the trial’s results to be a turning point for the company. LSD (lysergic acid diethylamide) is a potent hallucinogen that is synthetically manufactured from lysergic acid. It’s commonly known as acid, mellow yellow, doses and trips. When ingested in small doses, this hallucinogen produces mild changes in mood, thought and perception. The company has many projects using LSD, including…

WednesdayApr 20, 2022 1:30 pm

Study Links Psilocybin Mushrooms to Decreased Risk of Opioid Addiction

The past couple of years have seen a rise in the popularity of alternative medicines. As people become more aware of the risks and side effects associated with the use of pharmaceuticals, interest in safer alternatives has increased exponentially. Psychedelics such as magic mushrooms have enjoyed a lot of public attention as a result. Although research into the potential benefits and risks of psychedelics is just beginning, initial studies have found that they may possess the ability to alleviate anxiety, stress and depression. A study recently published in “Nature” has revealed that psilocybin, a hallucinogenic chemical found in magic mushrooms,…

TuesdayApr 19, 2022 3:26 pm

Legislators in Maryland Advance Psychedelic Research Measure to Governor’s Desk

Last week, legislators in Maryland advanced a measure to the governor that would establish a state fund to provide access to psychedelic drugs such as ketamine, MDMA and psilocybin free of charge to veterans suffering from traumatic brain injury and post-traumatic stress disorder (PTSD). The measure, which was introduced by Sen. Sarah Elfreth, cleared the House the week before. This comes after its unanimous approval in the Senate in March. This bill would establish a traumatic brain injury and PTSD alternative therapies fund. In its text, the bill stipulates that the monies from the fund would be used to study…

MondayApr 18, 2022 12:31 pm

Machine Learning Model Enables Researchers to Pinpoint PTSD Sufferers

Researchers have designed a machine learning model that can identify individuals suffering from PTSD by conducting an analysis of text data with 80% accuracy. Post-traumatic stress disorder (PTSD) is a mental health condition that is triggered by a traumatic event which an individual may witness or experience. This machine learning model may, in the future, be used as an inexpensive and accessible screening method to help physicians detect and diagnose post-traumatic stress disorder or other mental conditions, via telehealth platforms. Jeff Sawalha, a PhD candidate specializing in psychiatry at the University of Alberta, led this project. He carried out an…

ThursdayApr 14, 2022 4:00 pm

Psychedelics Could Help Combat Alcoholism

Recently conducted studies have found that psychedelics may be useful in the treatment of various mental conditions, including anxiety, depression and alcoholism. “Psychedelic” is a term coined by Dr. Humphry Osmond in the 20th century. Osmond, who specialized in psychiatry, theorized that some mental illnesses were brought about by chemical imbalances in the brain. Through his research in the ‘50s, he discovered that these hallucinogenic substances could be used to treat alcoholism. Alcoholism, or alcohol-use disorder, is defined as an addiction to drinking alcohol. The disorder develops as an individual drinks so much alcohol that their body becomes dependent on…

TuesdayApr 12, 2022 2:17 pm

Legislators in Colorado Pass MDMA Initiative But Reject Broader Psychedelics Proposal

Earlier last week, legislators in Colorado passed a measure that aligns statutes in the state to legalize MDMA prescriptions if the federal government allows its use. MDMA, which is commonly referred to as ecstasy, has shown promise in its use as a treatment for various indications, including anxiety and PTSD. The legislators made their decision after hearing testimonies from a number of people, including a military veteran who admitted that MDMA had helped him manage his post-traumatic stress disorder. This measure, which was unanimously approved, is being advanced to the floor. The House Public & Behavioral Health & Human Services…

MondayApr 11, 2022 2:50 pm

Top Federal Official Highlights Need to Enact Policy Changes for More Psychedelic Research to Be Conducted

During an event last week, top drug officials explained how the classification of substances such as cannabis and some psychedelics under Schedule I of the Controlled Substances Act hindered studies into the therapeutic potential of these substances from being conducted. The event, which focused on treatment using psychedelics, was organized by the National Academies of Sciences, Engineering and Medicine. Nora Volkow, director of the National Institute on Drug Abuse, has addressed the stressful process that researchers have to go through in order to acquire these controlled substances. During the event, Volkow explained that the scheduling process had made it hard…

FridayApr 08, 2022 3:12 pm

Oregon Health Authority Admits Proposed Psilocybin Rules May Negatively Impact Lower-Income Individuals

Recently, the Oregon Health Authority announced its latest revision of proposed rules at the start of this month. The rules were released ahead of the state’s psilocybin services program, which is scheduled to open to the private and public business sector in early 2023. Regarding its proposal, the Oregon Health Authority stated that the rules would impact all psilocybin testing laboratories, psilocybin facilitators, psilocybin service centers, psilocybin manufacturers and psilocybin training programs in the state. These rules, which focus on the manufacture and testing of psilocybin products and training modules for aspiring licensed facilitators, may have a negative effect on…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks